Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | PTGFR | P43088 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | GALK1 | P51570 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23796172 | 1.00 | PDE2A (0.48) | PDE2APTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL23796187 | 0.91 | PDE2A (0.51) | PDE2APTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL23795948 | 0.86 | CYP3A4 (0.45) | PDE2AP2RY14CYP3A4KCNH2KDM4E | |
| SCHEMBL30290004 | 0.86 | CYP3A4 (0.45) | PDE2AP2RY14CYP3A4KCNH2KDM4E | |
| SCHEMBL23796333 | 0.83 | KDM4E (0.43) | P2RY14CYP3A4KCNH2KDM4EAPAF1 | |
| SCHEMBL22559391 | 0.83 | PDE2A (0.44) | PDE2APTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL29754992 | 0.83 | PDE2A (0.44) | PDE2APTGER4PTGDRTBXA2RPTGER1 | |
| SCHEMBL22570620 | 0.79 | P2RY14 (0.54) | PDE2APTGER3P2RY14CYP3A4KCNH2 | |
| SCHEMBL30290120 | 0.79 | P2RY14 (0.54) | PDE2APTGER3P2RY14CYP3A4KCNH2 | |
| SCHEMBL23795892 | 0.78 | HDAC8 (0.46) | P2RY14KCNH2KDM4EAPAF1TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | PDE2A 4053/4885PTGER4 3668/4885PTGDR 1293/4885 |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | PDE2A 4053/4885PTGER4 3668/4885PTGDR 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.